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INTRODUCTIONPancreatic neuroendocrine tumors (PNETs) is the terminus suggested by the WHO for tumors deriving from the cells of the islets of Langerhans of the pancreas [1]. Other frequently used terms are pancreatic endocrine tumors or islet cell tumors. These tumors belong to the family of neuroendocrine tumors (NETs). NETs can be located in many different sites of the body. NETs are 
often classified as foregut, midgut and hindgut tumors [2]. They occur as sporadic and syndromic entities. Best known are NETs as a component of multiple endocrine neoplasia type 1 which 
is mainly formed by parathyroid adenoma, NET and pituitary adenoma. Less known is that NETs are also a component of von 
Hippel-Lindau disease (VHL). In VHL disease, NETs are almost exclusively located in the pancreas. In addition to PNETs the classic lesions of VHL disease are multiple serous pancreatic 
cysts or cystadenomas, hemangioblastomas of the retina and the 
central nervous system (CNS), clear cell renal carcinomas and pheochromocytomas [3].
SYMPTOMSPNETs may produce a variety of hormones or vasoactive peptides and can thus cause distinct endocrine syndromes. 
These include gastric ulcer, abdominal pain and diarrhea due to gastrinoma and an over secretion of gastrin, episodes of hypoglycaemia due to insulinoma and an over secretion 
of insulin, and other syndromes such as Werner Morrison syndrome due to an over secretion of vasoactive intestinal peptide (VIP) and glucagonoma due to an over secretion of glucagon. Such clinical presentations are known from sporadic 
or MEN1 associated PNETs. In contrast, VHL associated PNETs 
present almost exclusively as non-secreting endocrine tumors, 
as space occupying masses or metastases. Therefore, PNETs are mostly diagnosed in early adulthood with a mean age of about 35 years. PNETs associated with VHL are mostly diagnosed in an 
advanced stage except in individuals subjected to a VHL specific 
surveillance program. This underlines the importance of specific diagnostic strategies.
BIOCHEMISTRYSystematic analyses of serum concentrations of hormones in 
patients with VHL associated PNETs are pending, but secreting PNETs in VHL are extremely rare. Such analyses may include 
pancreatic polypeptide, gastrin, insulin, C peptide, VIP, glucagon, 
and somatostatin, and as an additional marker chromogranin A.
DIAGNOSIS OF PNETSPNETs can cause symptoms as local masses or by excretion of 
several hormones. Since introduction of serial imaging radiology 
techniques such as ultrasonography, computerized tomography 
(CT) and magnetic resonance imaging (MRI) the percentage of 
PNETs diagnosed as “incidentalomas”, as asymptomatic tumors, is rising. Finally the era of molecular genetics and molecular genetic diagnosis opened the doors to preventive medicine allowing the 
identification of particular tumors as specific manifestations of 
hereditary syndromic diseases. Once the diagnosis is established, 
the patients can be offered specific surveillance programs and 
protocols. Similarly, relatives can be tested for a given pathogenic mutation and can be clinically investigated. This is the way by which asymptomatic PNETs in VHL disease can be detected [4-8].
MOLECULAR GENETICS AND VHL PHENOTYPESVHL disease is an autosomal dominant disorder. The 
penetrance is age dependent, but high in affected subjects older than 40 years of age. The susceptibility genes for hereditary PNETs are the VHL gene located on chromosome 3p25-26 and the 
MEN1 gene predisposing for multiple endocrine neoplasia type 1 located on chromosome 11q13. The VHL gene has 3 exons and 
encodes the VHL protein with 213 amino acids. The MEN1 gene 
consists of 10 exons and encodes the Menin protein with 615 amino acids. Germline mutations are distributed over all exons 
of both genes, and in addition large deletions encompassing one 
to all exons of both genes have been described [6,9-15]. In VHL patients with PNETs all types of mutations have been described 
including missense mutations, stop codon mutations, intraexonic 
insertions and deletions, splice mutations and large deletions/
rearrangements [5,10,12,14,16] (Table 1). We have conducted a study to evaluate the frequency of germline mutations in unselected patients with NETs. Our 
registry-based approach used the German-NET-Registry with 
259 patients with the primary diagnosis of a NET. All patients 
provided blood DNA. All 10 exons of the MEN1 gene and all 3 exons of the VHL genes were analysed for intra-genic mutations 
and large deletions. In the NET-Registry, 9% of the patients with 
PNETs had germline mutations, 8 in MEN1 and 1 in VHL [16].
In addition, we evaluated the spectrum of VHL germline mutations and the corresponding phenotypes of all patients 
registered in the German VHL-Registry. The registry contained 
487 molecular genetically confirmed patients. All patients had magnetic resonance imaging or computed tomography 
of the abdomen. The prevalence of NETs was 53/487 (11%). 
Remarkably there were striking differences of occurrence of 
PNETs in patients with different mutations. Among patients with the mutation VHL p.R167W, 47% developed PNETs, compared to 
Abstract
Pancreatic neuroendocrine tumors (PNETs) occur in about 10% of patients with von Hippel-Lindau disease (VHL). Females are more frequently affected 
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malignant tumors include tumor debulking, nuclear radiation by [90Y] or [177Lu]-labelled DOTA-TATE or DOTA-TOC, somatostatin analogs, and tyrosine kinase 
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Nucleotide 
change Consequence
VHL Patients 
with ICT
Patients with the 
given mutation 
c.208 G>T p.E70X 1 1
c.221 T/G p.V74G 1 4
c.440_442delTCT p.F76CfsX83 1
c.240 T>G p.S80R 1 2
c.266 T/C p.L89P 1 7
c.277 G>C p.G93R 1
c.292 T>C p.Y98H 2 158
c.340 G>A p.G114S 1 1
c.349dupT p.W117LfsX1 1 1
c.357 C>G p.F119L 2 2
c.362 A>G p.D121G 1 1
c.364_365 GC>AT p.A122I 1 1
c. 393 C>A p. N131K 1
c. 394 C>T p. Q132X 1c.445_458del14 p.N150SfsX19 1 2
c.453 C>G p.I151M 1 1
c.461 C>T p.P154L 1 4
c.464-2 A>G Splice 2 4
c. 467 A>G p. Y156C 1
c.472 C>G p.L158V 1 1
c.478_479delGA p.E160AfsX12 2 3
c.482 G>A p.R161Q 5 8
c.482 G>C p.R161P 1 2
c.488 T>A p.L163H 1 2
c.499 C>T p.R167W 7 15
c.500 G>A p.R167Q 4 5
c.533 T>C p.L178P 1 1
c.548 C>A p.S183X 1 4
c.583 C>T p.Q195X 1 3
c. 593 T>A p. L198Q 2Large Deletions* 6 63
Table 1: VHL germline mutations in VHL patients with PNETs [16].
* indicates deletions of 1, 2 or 3 exons of the VHL gene.
Variables  VHL Sporadic p-value
Age (years) mean 36.03 57.07
<0.001
 SD 11.13 11.98
Sex female 34 37
0.010male 20 55
Tumor Number single 41 64
0.011multiple 13 5
Tumor Biology benign 39 24
<0.001malignant 15 68
Pancreatic Tumor as First 
Presentation
yes 2 92
<0.001no 52 0
Family History of VHL
positive 32 1
<0.001negative 22 91
Table 2: Comparison between VHL-related and sporadic PNETs [16].
p-values of Chi-square or Fisher test considered to be significant are represented in bold.
Abbreviations: SD for standard deviations, VHL for von Hippel-Lindau disease.
Figure 1 A neuroendocrine tumor of the pancreatic head (arrows), CT 
scan, early arterial phase.
Figure 2 Two pancreatic neuroendocrine tumors (arrows), CT scan, early arterial phase.
Figure 3 A neuroendocrine tumor of the distal part of the pancreas 
(tail) (arrows), MRI, early arterial phase.
Figure 4 Very small pancreatic neuroendocrine tumor (arrows), MRI. Note that the early arterial phase was instrumental to detect this small tumor.
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only 2% of those with the mutation p.Y98H.
In total, there were 92 truly sporadic, i.e. mutation-negative 
PNET patients. Comparing these 92 patients to 54 VHL patients, 
statistically significant differences were predominance of female 
gender, multifocal PNETs and lower malignancy rate in VHL 
compared to sporadic cases [16] (Table 2).
In summary, PNETs are rarely the first presentation of 
VHL disease. Therefore, molecular genetic testing for germline mutations of the VHL gene is not generally recommended for 
all patients with PNETs, unless they have multifocal tumors, 
associated, VHL-specific tumors and/or a family history for VHL disease.
COMPUTERIZED TOMOGRAPHY AND MAGNETIC 
RESONANCE IMAGING
PNETs can be accurately diagnosed by computerized 
tomography (CT) and magnetic resonance imaging (MRI) (Figures 
1 – 4) [17,18]. MRI is the method of choice because of the absence of radiation and no contrast medium side effects in patients with normal renal function. Imaging in the early arterial phase is essential. It must be performed 1st 20 seconds, 2nd between 
20 and 40 seconds and 3rd within 2 minutes after i.v. contrast 
application. All tumors need to be exactly measured in 2, better 
in 3 dimensions. Actual and former images have to be compared. 
Newly identified tumors may be visible retrospectively in former 
images due to a small size or lack of contrast uptake. It takes much 
of the burden from a patient, if the information can be provided 
that the tumor is not new and the growth rate can be defined.
NUCLEAR MEDICINE IMAGINGSeveral radiopharmaceuticals are used in the diagnostic 
of PNETs (Figure 5). The somatostatin receptor (SSTR) ligand 111In-DTPA-octreotide (OctreoScan®) has been extensively used 
for SSTR scintigraphy and single-photon emission tomography 
(SPECT; or hybrid SPECT/CT). However, 111In-DTPA-octreotide imaging has been replaced whenever available by positron emission tomography (PET; commonly performed as hybrid 
PET/CT) using SSTR-ligands. Currently, three DOTA-coupled 
peptides: DOTATOC (Tyr3-octreotide), DOTATATE (Tyr3-
octreotate), and DOTANOC (Nal3-octreotide) have excellent 
affinity for SST2 receptors (IC50: 2.5 nM; 0.2 nM; and 1.9 nM 
respectively). DOTA-NOC also binds specifically to SST3, SST4 and SST5 receptors. Physiological distribution is similar to 111In-
DTPA-octreotide. Additionally, tracer uptake is frequently found in the pancreas particularly in the processus uncinatus mimicking a focal tumor uptake.
SSTR PET/CT offers superior image resolution, lesion-to-background contrast and thus overall diagnostic accuracy. 
Sufficient SSTR expression as imaged by SSTR imaging is also a prerequisite for possible peptide receptor radionuclide therapy 
(PRRT) in advanced, inoperable cases using beta-particle emitting 
SSTR ligands like 90Y- or 177Lu-labelled DOTA-TATE or DOTA-
TOC (for a recent review see [26]). In addition, PET scanning with [18F] fluorodopa ([18F]-FDOPA) or [18F] fluorodeoxyglucose (FDG; especially in higher proliferating tumors) may be helpful in some cases. Pancreatic NETs exhibit variable [18F]-FDOPA uptake patterns. The main drawback of the technique is related to the intense and prolonged [18F]-FDOPA uptake by the exocrine 
pancreas, resulting in a low tumor-to-background uptake ratio. The optimal timing for acquisition and the use of oral 
premedication with carbidopa, a peripheral aromatic amino acid decarboxylase (AADC) inhibitor, remains to be evaluated.
DIFFERENTIAL DIAGNOSISThe most relevant differential diagnosis of PNETs in VHL are pancreatic serous cystadenomas. Common in VHL are multiple pancreatic cysts. Cystadenomas consist of micro cystic 
structures and are related to benign pancreatic cysts. Whenever, 
seemingly solid lesions of the pancreas have a cystic component, 
cystadenomas are very likely. In contrast to PNETs, metastases due to VHL associated cystadenomas have not been described. 
Therefore, surgical removal is rarely indicated. This is of outstanding importance for lesions which cannot be removed by endoscopic organ sparing techniques.
In VHL, NETs outside the pancreas are extremely rare, but a 
patient with a carcinoid has been described [19].
SURGERY FOR PNETS IN VHL
Pancreatic surgery should only be performed in specialized 
centers, and experience with VHL patients is extremely important. Excellent imaging is the fundamental platform for successful surgery. Indication for surgery depends on the type of pancreatic lesion. Pancreatic cysts and cystadenomas do not need surgical treatment. Two different surgical methods must be considered 
for solid lesions depending on the size and number of the tumors. 
In smaller lesions, where malignancy is very unlikely an organ preserving tumor removal is indicated. In cases of evidence or suspect of malignant PNETs more extended resections should be 
considered [4,20].Classical surgery with laparotomy is the method of choice 
for PNETs of the head, the proximal corpus and the processus uncinatus of the pancreas.It is important to operate as less invasive as possible. Especially for small tumors enucleation is the procedure of choice. Intraoperative ultrasonography is excellent to screen for 
undetected, potential multifocal disease and to plan resections 
close to the pancreatic duct to lower the risk of pancreatic fistula.
Figure 5 Malignant pancreatic neuroendocrine tumor. The pancreatic 
tumor was removed months before. The 68Gallium DOTATATE PET shows multiple liver metastases. Normal uptake of the tracer in the spleen and both kidneys.
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Partial pancreaticoduodenectomy is the surgical strategy 
for large tumors. In the classic Whipple´s procedure duodenum, 
regional lymph nodes, gastric antrum, gallbladder, and distal bile tract are removed together with the resected pancreatic 
head. The modification by Traveso and Longmire preserves the pylorus and represents the procedure of choice in most oncologic resections. Removal of tumors infiltrating the portal vein is not 
contraindicated. For reconstruction of the biliary tract, intestinal 
passage, and drainage of the pancreatic tail a wide variety of safe surgical techniques are available. Postoperative complications 
include pancreatic fistula, hemorrhage, delayed gastric emptying, diabetes mellitus and malnutrition; they have been widely 
avoided by modification of the surgical technique, improved postoperative care and interventional endoscopic and radiologic 
treatment of complications [21].
Minimally invasive surgery is preferred in selected PNETs of the pancreatic tail and the distal pancreatic body. Best candidates are patients with tumors less than 3 cm in diameter and without lymph node metastases. The approach will be laparoscopic or retroperitoneoscopic. Preservation of the spleen should be 
intended [22]. In a first series 3 patients were operated by the 
laparoscopic approach. Operating time ranged between 215 – 360 
min. Due to infiltrations and/or adhesions of the splenic vein, the spleen could be preserved only in one case. One patient turned 
out to have a malignant PNET with lymph node metastases [21].
HISTOPATHOLOGYImmunohistochemical demonstration of the neuroendocrine nature of the tumor is mandatory for the diagnosis of PNET 
[23]. PNETs are usually positive for the general neuroendocrine markers synaptophysin and chromogranin; additionally 
immunoreactivity for cytokeratin, insulin, gastrin, glucagon, 
somatostatin and/or neurospecific enolase (NSE) may be 
encountered. PNETs may show a trabecular, solid, and/or 
glandular growth pattern. The cells are often uniform, the 
finely granulated cytoplasm is usually eosinophilic [24,25]. It 
is important to emphasize that there is a lack of clearly defined histological criteria for malignancy. Textbooks such as the 
WHO classification of tumors compare clinical features and 
histopathological findings, but neither a single morphological 
criterion nor a combination of criteria, e. g. the “classical” stigmata 
of malignancy such as cell atypia, mitoses and vascular invasion, can be applied for precise prediction of clinical behaviour. Even 
the demonstration of tumor infiltration of adjacent tissue is not generally accepted as a hallmark of malignancy. Cellular grading 
as G2, in contrast to G1, a Ki-67 proliferation index, which is 
also mandatory for reporting PNETs, of >20% and more than 
20 mitoses per 10 high power vision fields are often the basis 
for reports of malignant neuroendocrine tumors. However, the only proof for malignancy are lymph node or distant metastases 
[1,24].
TREATMENT OF MALIGNANT PNETS AND 
METASTASESTreatment of malignant PNETs is a challenge on its own. In 
contrast to adenocarcinoma of the pancreas, PNETs are slowly 
growing tumors, and all activities are justified. The primary goal is complete removal of the tumor and potential metastases. If not 
possible, as much tumor tissue as possible should be resected 
(debulking). After surgical treatment, MRI and nuclear medicine 
imaging (preferably SSTR PET/CT) should be repeated. In case of 
advanced, inoperable tumors or tumor remnants, PRRT with 90Y- or 177Lu-labelled DOTA-TOC or DOTA-TATE is the next option. 
PRRT is commonly performed in 3 to 6 cycles in 2-3 months 
intervals [26]. In parallel or after this treatment long acting somatostatin should be started. Systemic treatment on malignant 
PNET involves multitarget tyrosine kinase inhibitors (semaxanib, 
sunitinib and vatalanib), thalidomide and interferon alpha-2a which are widely studied to prolong disease stability. Salvage therapy with anti-angiogenesis drugs has also been shown to be 
of benefit in some patients not suitable for surgery [27-29].
FOLLOW UP STRATEGIES
The method of choice for follow up investigations is MRI with early arterial phase imaging. Patients with PNETs need a strict follow up. This is true for patients with small PNETs so far not requiring surgery and for patients who underwent 
surgery. Since only about 10% of all VHL patients have a risk 
for PNETs it is of debate how long follow up intervals should be, 
if an actual MRI gives no evidence for such tumors. There is no 
general international agreement, but being aware that PNETs are 
indolent, slowly growing tumors, intervals of 2 or even 3 years seem adequate.
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